Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesNext Science Ltd

Next Science Ltd

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
None AUD 0.00(0%)
Last update at 2026-03-11T06:45:05.996063Z
Market Cap
42.43M

Momentum Score

…

Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.06
Low
0.15
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
22.07M
Revenue Per Share
0.08
Gross Profit TTM
18.20M
Debt / Equity
0.72
ROE
-289.70%
Net Debt
0.82M
ROCE
-171.84%
Diluted EPS TTM
-0.05

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -10.59M -16.27M -12.68M -9.35M -11.91M
Net income -10.59M -24.51M -11.83M -9.36M -11.84M
Selling general administrative 6.75M 5.61M 5.39M 3.91M 3.14M
Selling and marketing expenses 16.07M 20.17M 10.31M 7.37M 5.65M
Gross profit 18.44M 16.23M 9.15M 6.94M 2.92M
Reconciled depreciation 1.27M 1.11M 0.90M 0.79M 0.91M
Ebit -10.30M -15.53M -13.55M -9.60M -12.52M
Ebitda -9.03M -14.42M -12.65M -8.81M -11.82M
Depreciation and amortization 1.27M 1.11M 0.90M 0.79M 0.70M
Operating income -10.30M -15.95M -13.55M -9.60M -12.52M
Other operating expenses 33.12M 38.13M 25.31M 18.56M 15.97M
Interest expense 0.28M 0.74M -0.02M 1.04M 0.61M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.04M 0.47M 0.01M 0.13M 0.14M
Net interest income -0.28M -0.32M -0.02M 0.00M 0.11M
Income tax expense - 0.00M -0.85M 0.01M -0.08M
Total revenue 22.82M 22.18M 11.71M 8.95M 3.44M
Total operating expenses 28.75M 32.19M 22.74M 16.55M 15.45M
Cost of revenue 4.37M 5.94M 2.56M 2.01M 0.52M
Total other income expense net -0.28M -0.32M 0.87M 0.25M 0.61M
Net income from continuing ops -10.59M -16.27M -12.68M -9.35M -15.47M
Net income applicable to common shares -10.59M -16.27M -12.68M -9.35M -11.91M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 9.21M 17.90M 12.46M 13.72M 23.64M
Intangible assets 0.83M 2.39M 2.41M 2.53M 2.33M
Other current assets 0.34M - 0.54M 0.48M 0.45M
Total liab 5.77M 5.08M 4.42M 2.95M 4.73M
Total stockholder equity 3.44M 12.82M 8.04M 10.77M 18.91M
Deferred long term liab - - 1.37M 1.49M 1.37M
Other current liab 2.07M - 1.10M 0.77M 0.57M
Common stock 133.93M - 113.53M 102.92M 101.28M
Capital stock - 133.82M 113.53M 102.92M 101.28M
Retained earnings -89.10M -78.51M -63.13M -50.45M -41.10M
Other liab - - 0.85M 1.30M 1.38M
Other assets - - 0.04M 1.52M 1.41M
Cash 1.67M 9.24M 5.07M 7.00M 8.10M
Total current liabilities 3.22M 3.84M 2.61M 1.54M 3.23M
Current deferred revenue - - 0.27M 0.09M 1.91M
Net debt 0.82M - -3.85M -6.72M -7.81M
Short term debt 0.22M - 0.26M 0.17M 0.17M
Short long term debt total 2.49M - 1.22M 0.28M 0.29M
Other stockholder equity - - -1.91M -41.71M -41.27M
Property plant equipment - - 1.75M 0.92M 1.02M
Total current assets 6.05M 13.96M 8.26M 10.23M 20.25M
Net tangible assets - - 6.99M 9.72M 17.95M
Short term investments - 0.04M 0.04M 0.37M 7.24M
Net receivables 3.31M 3.46M 1.74M 0.89M 3.39M
Inventory 0.73M 0.72M 0.87M 1.50M 1.07M
Accounts payable 0.93M 1.41M 0.97M 0.52M 0.57M
Accumulated other comprehensive income -41.39M - -42.36M -41.71M -41.27M
Common stock total equity - - - - 131.50M
Non currrent assets other 1.26M - 0.04M 0.04M 0.04M
Non current assets total 3.16M 3.94M 4.20M 3.49M 3.39M
Capital lease obligations - 0.96M 1.22M 0.28M 0.37M
Long term debt total - - 0.96M 0.11M 0.12M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -0.59M -0.88M -0.48M -0.72M -0.89M
Change to liabilities - - 0.53M -1.80M 1.55M
Total cashflows from investing activities -0.59M -0.88M -0.48M -0.72M -0.69M
Net borrowings 2.00M - -0.25M -0.21M -0.22M
Total cash from financing activities 1.75M 20.11M 10.25M 1.43M 10.71M
Change to operating activities - - -0.39M -0.06M 0.00M
Net income -10.59M -23.87M -11.83M -9.35M -11.30M
Change in cash -7.56M 4.17M -2.26M -7.97M -1.57M
Begin period cash flow 9.24M 5.07M 7.37M 15.34M 16.91M
End period cash flow 1.67M 9.24M 5.11M 7.37M 15.34M
Total cash from operating activities -7.96M -15.06M -10.94M -8.26M -11.91M
Issuance of capital stock - 21.02M 10.89M 1.65M 11.32M
Depreciation 1.27M 1.68M 0.90M 0.79M 0.70M
Other cashflows from investing activities -0.54M -0.59M - - -
Change to inventory 0.00M 0.27M 0.56M -0.39M -0.63M
Change to account receivables 0.25M -1.91M -0.81M 2.50M -2.10M
Sale purchase of stock 0.00M -0.64M -0.39M -0.01M -0.39M
Other cashflows from financing activities -0.25M -6.98M -0.25M -0.21M -0.22M
Change to netincome - - 0.10M 0.04M 0.47M
Capital expenditures 0.59M 0.88M 0.48M 0.72M 0.69M
Change in working capital 0.85M -2.18M - -17.78M -14.86M
Stock based compensation 1.01M 0.20M - - -
Other non cash items -0.51M 10.99M 10.94M 8.56M 11.00M
Free cash flow -8.55M -15.94M -11.41M -8.98M -12.59M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AFP
Aft Pharmaceuticals Ltd		 -
-%		 3.59 29.92 18.18 1.48 4.37 2.05 18.56
VLS
Vita Life Sciences Ltd		 -
-%		 2.70 13.50 42.73 1.52 2.62 1.19 7.17
LGP
Little Green Pharma Ltd		 -
-%		 0.06 - 10.00 0.64 0.60 1.25 19.47
MVP
Medical Developments International Ltd		 -
-%		 0.40 40.00 166.67 1.06 0.79 0.57 7.45

Profile*

Next Science Ltd

Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.

Australia Square, Sydney, NSW, Australia, 2000

61 4 1229 2977

https://www.nextscience.com

Name Title Year Born
Ms. Judith Mitchell M.B.A. MD, CEO & Exec. Director NA
Dr. Matthew Franco Myntti Founder & CTO NA
Ms. Jacqueline Butler CA (ICAEW) Chief Financial Officer NA
Mr. Jon Swanson Chief Operating Officer NA
Mr. Michael Morello VP of Sales NA
Ms. Gillian Maria Nairn AGIA, B.A., BA, L.L.B., L.L.M., LLB, LLM, MAICD Company Sec. NA
Mr. Harry Thomas Hall MD, CEO & Director NA
Marc Zimmerman Chief Financial Officer NA
Mr. Robert Bell Senior Vice President of North American Sales NA
Ms. Gillian Maria Nairn AGIA, B.A., BA, L.L.B., L.L.M., LLB, LLM, MAICD Company Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…